Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Tango Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Robert Azelby, Director (Form 8-K filed 2026-06-23). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names The Goldman Sachs Group, Inc. (filed 2026-08-14).
Who is behind it
Tango Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- Barbara Weber: Executive Officer, Director (Form D, 2025-10-28)
- Daniella Beckman: Executive Officer (Form D, 2025-10-28)
- Adam Crystal: Executive Officer (Form D, 2025-10-28)
- Alexis Borisy: Director (Form D, 2025-10-28)
- Lesley Ann Calhoun: Director (Form D, 2025-10-28)
- Malte Peters: Director (Form D, 2025-10-28)
- Mace Rothenberg: Director (Form D, 2025-10-28)
- Kanishka Pothula: Director (Form D, 2025-10-28)
- John Ketchum: Director (Form D, 2025-10-28)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | The Goldman Sachs Group, Inc. | 6% |
| Schedule 13G/A, 2026-08-14 | Tcg Crossover Gp Ii, LLC | 7% |
| Schedule 13G/A, 2026-08-14 | Woodline Partners LP | 2.5% |
| Schedule 13G/A, 2026-08-14 | Nextech Crossover I Gp S.A. R.L. | 0% |
| Schedule 13G/A, 2026-08-14 | Farallon Capital Management, L.L.C. | 9.8% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 3.44% |
| Schedule 13G/A, 2026-05-15 | Woodline Partners LP | 5.6% |
| Schedule 13G/A, 2026-05-15 | Tcg Crossover Gp Ii, LLC | 8.1% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-23 | Robert Azelby | Director | appointed | 2026-06-19 |
| Form 8-K, 2026-05-13 | Alexis Borisy | Lead Independent Director | departed | 2026-05-13 |
| Form 8-K, 2026-05-13 | Kanishka Pothula | departed | 2026-05-13 | |
| Form 8-K, 2026-04-15 | Matthew Gall | Chief Financial Officer | appointed | 2026-04-15 |
| Form 8-K, 2026-04-15 | Jessica Newcomb | appointed | 2026-04-15 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-10-28 | $15M | $15M |
| Form D, 2023-08-24 | $80.02M | $80.02M |
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/tango-therapeuticsLast updated 2026-10-18
Primary record: Schedule 13G, 2026-08-14 · Form D, 2025-10-28 · Form 8-K, 2026-06-23 · Form 8-K, 2026-05-13
Who owns Tango Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/tango-therapeutics